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1. Introduction 
Stroke is a major cause of serious, long-term disability and the third leading cause of death 
in the United States1. According to the World Health Organization, 15 million people suffer 
a stroke worldwide annually. Of those, one third do not survive and another third is left 
with a significant neurological deficit. The majority of these events are ischemic (87%), as 
opposed to intracerebral (10%) and subarachnoid hemorrhages (3%)1. Management of acute 
ischemic stroke was previously geared toward prevention, supportive care, and 
rehabilitation. Over the past few decades, however, the medical management of stroke has 
progressed exponentially, beginning with the US Food and Drug Administration (FDA) 
approval of tissue plasminogen activator (r-TPA, alteplase) in 1996. Intravenous 
administration of r-TPA within a limited 3-hour window from symptom onset has shown a 
significant improvement in patient outcome at 3 months and at one year following an acute 
cerebrovascular event.2 Current stroke guidelines have extended the therapeutic r-TPA 
administration window to 4.5 hours. 
The intra-arterial (IA) injection of therapeutic agents was first published nearly 60 years ago, 
when Sussman and Fitch described the IA treatment of acute carotid occlusion with 
fibrinolysin injection in 1958.3 It was not until the late 1990’s that the endovascular 
management of acute stroke experienced exponential progress and development. Recent 
advances in endovascular techniques have increased the therapeutic window of r-TPA 
administration and introduced new agents such as reteplase and abciximab. Furthermore, 
the use of IA devices for clot retrieval and vessel recanalization has revolutionized the 
neuroendovascular management of acute ischemic stroke. 
2. Patient selection 
The goal of endovascular management of acute ischemic stroke is to enhance the survival 
of local ischemic brain tissue (penumbra) and limit the extent of infarcted brain 
parenchyma. An initial evaluation with a non-contrast computerized tomography (CT) 
head scan is necessary. In a retrospective review of 85 patients from the Penumbra Pivotal 
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Stroke Trial, Goyal and colleagues found that a baseline CT scan by ASPECTS score>7 
(Alberta Stroke Program Early CT Scale) had a 50% chance of a favorable clinical outcome 
with early recanalization (p=0.0001). In addition, ASPECTS scores of less than 4 did not 
show clinical improvement regardless of endovascular recanalization4. Patients with large 
territorial infarcts on CT scan are at a higher risk for hemorrhagic conversion following 
treatment and are therefore poor candidates for endovascular therapy.5  In addition, the 
presence of an intra-parenchymal hematoma is a contraindication to endovascular 
recanalization. Lastly, the presence of a hyperdense MCA sign on the initial head CT does 
not have a significant prognostic value in patient outcome and vessel recanalization 
rates.6-8 
Over the past decade, the clinical application of CT perfusion scans has facilitated the pre-
treatment evaluation of “salvageable” tissue. A scan consistent with a mismatch between 
cerebral blood volume (CBV, “core” cerebral lesion volume) and cerebral blood flow or 
mean transient time (CBF or MTT, “penumbra” lesion volume) is a favorable patient 
selection criterion.9 In our institution, a favorable CT perfusion scan may overcome the six-
hour post-symptom onset time restriction. 
Although patient age and initial National Institutes of Health Stroke Scale score (NIHSS) do 
not show statistically significant correlation with post-treatment intracranial hemorrhage 
(ICH), careful attention should be paid to both.5 In a recent retrospective review of 156 
patients, Zacharatos and colleagues found that thrombolytic therapy (chemical or 
mechanical) showed a favorable clinical outcome versus supportive management in the 80 
years and older age group10. However, patient co-morbidities are evaluated prior to 
treatment. Specifically, the presence of hyperglycemia, defined as blood sugar levels greater 
than 200mg/dl within 24 hours from presentation, can significantly increase the likelihood 
of post-thrombolysis hemorrhagic conversion.5  
Previous administration of intravenous tPA is not a contraindication to IA intervention. 
However, the hemorrhagic complications in these patients are significantly higher, 
especially if urokinase was the arterial agent.5 One must therefore clearly explain the risks 
and benefits of the procedure to the family and include them in the decision making 
process. Overall, endovascular intervention is an invaluable tool in the management of acute 
ischemic stroke. However, the duration of ischemia and the presence of viable ischemic 
tissue in excess of irreversibly damaged tissue are both critical factors in the successful 
management of acute stroke.  
3. Angiographic evaluation 
Initial angiographic evaluation of the patient’s vasculature is of paramount importance for 
the establishment of the ischemic etiology and initiation of treatment. Thus far, the use of 
general anesthesia is preferred due to motion elimination contributing to procedural safety 
and efficacy11. However, newer studies suggest that conscious sedation or local anesthesia 
may lead to more favorable radiographic and clinical outcomes by decreasing time delay 
and cerebral ischemia from hypoperfusion11-13. Femoral access is established in the 
symptomatic lower extremity, if no vascular contraindications exist. A thorough 
examination of the cerebrovascular anatomy begins with the aortic arch. The 
brachiocephalic vessels are visualized and any proximal stenosis, irregularities or occlusion 
noted. Proximal vessel disease may require immediate treatment with balloon angioplasty 
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and/or stenting to allow access to the intracranial pathology or may itself be the cause of the 
acute ischemic event. 
Based on the patient symptomatology and pre-procedure imaging, selective 
catheterization of the carotid or vertebrobasilar circulation supplying the affected territory 
is performed. Attention is paid to the extracranial collateral circulation, the 
leptomeningeal anatomy, the circle of Willis, and overall global cerebral perfusion. Recent 
data showed that the grade of angiographic collaterals is a decisive factor for the degree 
of reperfusion and clinical improvement following endovascular intervention in acute 
ischemic stroke14. 
The modality of treatment (for example IA thrombolysis, balloon angioplasty, stenting, clot 
retrieval mechanisms) is tailored to each individual case. At times, advanced age or 
significant atherosclerotic disease may limit treatment options. 
4. Intra-arterial chemical thrombolysis 
Over the past decade, several agents have been investigated for IA thrombolysis with 
variable dosages and administration routes. Overall, these drugs act by activating 
plasminogen to plasmin, which in turn degrades fibrin and its associated derivatives. 
Although studies targeting direct comparisons of the different agents have not yet been 
published, fibrin-specific agents, such as recombinant tissue plasminogen activator (r-tPA) 
and recombinant pro-urokinase (rpro-UK) have been widely studied and used most 
frequently.15  
First-generation agents, such as streptokinase and urokinase, are non-fibrin selective and 
could therefore have greater systemic complications.16 Streptokinase, a protein derivative 
from group C beta-hemolytic streptococci, has a half-life of 16-90 minutes. It has an 
increased association with intracranial and systemic hemorrhages, and was therefore 
removed from the chemical armamentarium for the management of acute ischemic stroke.17  
Urokinase, a serine protease, has a half-life of 14 minutes and dosage range of 0.02-2 million 
units.18 
Second-generation agents have a higher fibrin-specificity and are most commonly studied in 
IA stroke management studies. Alteplase (r-tPA), also a serine protease, has a half-life of 3.5 
minutes and a dosage range of 20-60 mg.18  The precursor of urokinase (rpro-UK) has a half-
life of 7 minutes and may be favorable to r-tPA due to decreased side effects. Kaur and 
colleagues published potential neurotoxic properties of alteplase, such as activation of 
NMDA receptor in the neuronal cell-death pathway, amplification of calcium conductance, 
and activation of extracellular matrix metalloproteinases.19 These effects may facilitate 
exacerbation of cerebral edema, disturbance of the blood brain barrier, and development of 
ICH. 
Third-generation agents, such as reteplase and tenecteplase, have longer half-lives (15-18 
minutes) and theoretically favorable vessel recanalization and local recurrence rates.16  
Newer -generation agents are genetically engineered, such as Desmoteplase and 
Microplasmin (Thrombogenics, Heverlee, Belgium). 
Besides their fibrinolytic properties, the aforementioned agents have prothrombotic 
effects by the production of thrombin during thrombolysis, and subsequent activation of 
platelets and fibrinogen.16  As a result, concomitant use of systemic anticoagulation 
during IA thrombolysis is recommended with caution to risk of ICH. The most widely 
used adjuvant systemic agent is heparin. Newer generation agents under the category of 
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glycoprotein (GP) IIIb/IIa antagonist, such as Reopro (abciximab) and Integrilin 
(eptifibatide) are currently under investigation. Memon and colleagues reviewed 35 cases 
of adjunctive use of eptifibatide in salvage reocclusion and thrombolysis of distal thrombi 
with a single bolus of 180µg/kg. They reported a partial to complete recanalization of 
77%. However, incidence of post-operative hemorrhage was 37% and symptomatic in 14% 
of patients20. 
4.1 Anterior circulation 
4.1.1 Middle cerebral artery 
Three major clinical trials evaluated the efficacy of IA thrombolysis in the Middle Cerebral 
Artery (MCA) circulation, specifically the PROACT I and II (Prolyse in Acute Cerebral 
Thromboembolism), and MELT trials (Middle Cerebral Artery Local Fibrinolytic 
Intervention Trial). Although IA thrombolysis shows a favorable outcome in the setting of 
acute ischemic injury, FDA approval has thus far been granted for its intravenous 
counterpart alone.21 
In 1998, del Zoppo and colleagues presented a phase II clinical trial investigating the safety 
and efficacy of IA delivery of recombinant-pro-urokinase (rpro-UK) in acute MCA stroke, 
PROACT I.22 Following the exclusion of intracranial hemorrhage with a non-contrast head 
CT, 40 patients were randomized for treatment of acute ischemic stroke within 6 hours of 
symptom onset. Cerebral angiography was performed, and M1 or M2 occlusions were 
treated with 6 mg of rpro-UK (n=26) or placebo (n=14).  All patients received a concomitant 
heparin bolus followed by a 4-hour infusion. The final endpoints were recanalization 
efficacy at the end of the infusion period and neurological deterioration from intracranial 
hemorrhage (ICH) within 24 hours of treatment. Rpro-UK treated patients had higher vessel 
recanalization rates compared to placebo (57.7% versus 14.3%). Furthermore, the incidence 
of ICH was higher in the rpro-UK group (15.4% versus 7.1%). Overall, PROACT I was the 
first organized trial proving the safety and efficacy of IA thrombolysis for the management 
of acute ischemic stroke. 
PROACT II was a subsequent phase III clinical trial that studied the safety and efficacy  
of rpro-UK in a larger patient population (n=180).23 This randomized, controlled clinical 
trial treated patients with MCA occlusion within 6 hours of symptom onset with either 9 
mg of IA rpro-UK and heparin infusion (n=121) or heparin infusion alone (n-59). The 
study’s primary endpoint was the 90-day patient neurological disability based on the 
modified Rankin score scale. Secondary outcomes included mortality, vessel 
recanalization, and neurological deterioration from the development of ICH. Patients who 
received IA rpro-UK had significantly lower Rankin scores at the 90-day endpoint 
compared to heparin only treated patients. Furthermore, the MCA racanalization and 
mortality rates favored the rpro-UK group as opposed to the control group (66% versus 
18%). Albeit a higher incidence of ICH in the rpro-UK group (10% as opposed to 2% in the 
control group), the PROACT II multicenter trial demonstrated that the use of IA chemical 
thrombolysis in acute ischemia of the anterior circulation leads to radiographic and 
clinical improvement. 
Recently, the MELT Japanese study group investigated the IA administration of UK in the 
setting of MCA stroke within 6 hours of onset.24 Although the study showed favorable 90-
day functional outcome in the UK-treated patients with respect to controls, results did not 
reach statistical significance. Unfortunately, the investigation was aborted prematurely 
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following the approval of intravenous r-TPA in Japan for the treatment of acute ischemic 
stroke. 
The optimal window for IA thrombolysis in the anterior circulation has been investigated in 
multiple clinical trials. Overall, results show that IA treatment of acute MCA infarction 
outweighs potential hemorrhagic risks when implemented within a 6-hour window from 
symptom onset.15 Theron et al investigated the efficacy of IA thrombolysis in patients with 
acute internal carotid artery (ICA) occlusion as it related to the timing of treatment and 
angiographic location.25  Based on his work, IA fibrinolysis of the MCA should be 
performed within 6 hours from ischemia onset, when the occlusion involves the horizontal 
segment of the MCA extending into the lenticulostriate arteries. Treatment complications, 
mainly hemorrhagic incidence, increase significantly beyond this optimal time-frame. 
However, if the occlusion does not involve the horizontal MCA segment and the 
lenticulostriate arteries, then the treatment window can be extended to 12 hours following 
symptoms.15  The paucity of collateral circulation in the lenticulostriate arteries, as well as 
their distal distribution, both contribute to their sensitivity to ischemia in the setting of acute 
stroke. When initiating endovascular intra-arterial thrombolysis, the operator should 
account for time required to perform the procedure. Considering that the average 
intervention time varies from 45 to 180 minutes, high-risk patients should be treated within 
4-5 hours from ischemia onset.26-28 
4.1.2 Internal carotid artery 
Occlusions of the proximal ICA (extra-cranial) generally have a better prognosis than 
intracranial occlusions. The presence of external-internal carotid collateral flow and the 
anastomosis at the circle of Willis account for this observation. Patients with insufficient 
extracranial-intracranial anastomoses or an incomplete circle of Willis may be predisposed 
to developing significant neurological symptoms. These patients are potential candidates for 
IA intervention. In these cases, mechanical thrombolysis, in addition to pharmacological 
thrombolysis, is of paramount importance for recanalization. In a 25-patient series, Jovin 
and colleagues demonstrated successful revascularization in 92 % of patients following 
thrombolysis and ICA stenting.29  
Intracranial ICA acute occlusions have a dismal natural history and overall prognosis. 
Negative prognostic factors include distal ICA distribution involving the M1 and A1 
segments (“T” occlusion) and poor neurological presentation. Furthermore, as observed 
by Bhatia et al, recanalization following IV r-tPA in patients with T occlusion is the lowest 
at 4.4%30. Arnold and colleagues presented a series of 24 patients with distal ICA 
occlusions treated with IA urokinase. Favorable 3-month functional outcome was present 
in only 16% of patients, and the mortality rate was approximately 42%.31 Adjuvant 
mechanical assistance with devices for balloon angioplasty, clot retrieval, and vessel 
stenting enhance the probability of vessel recanalization (Fig. 1). Flint et al published a 
series of 80 patients with ICA occlusion who were treated with combinations of the Merci 
retriever (Concentric Medical, Mountain View, California) with or without adjunctive 
endovascular therapy. Recanalization rates were higher in the combination group (63%) 
as opposed to the Merci group (53%). At a 3-month follow-up, 25% of patients had a good 
neurological outcome, with their age being a positive predictive indicator.32  Overall, 
these results are encouraging, and IA intervention in select cases of acute ICA occlusion 
should be considered. 
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Fig. 1. A-E. Acute left ICA occlusion. The patient presented 6 hours following onset of global 
aphasia and R hemiplegia. A-B. Mid-arterial digital subtraction angiogram of left ICA artery 
showing complete occlusion of the distal ICA (T occlusion), frontal and lateral views.  
C. Frontal view of balloon angioplasty and recanalization of the distal left ICA.  
D-E. Frontal and lateral views of left ICA angiograms following mechanical and chemical 
recanalization with balloon angioplasty, Merci device, and administration of of Urokinase.  
4.1.3 Central retinal artery 
Occlusion of the Central Retinal Artery (CRA) is an ophthalmologic emergency with a 
natural history that leads to loss of vision. Conventional medical therapy includes ocular 
massage, carbohydrate inhibitors, inhalation of carbogen mixture, paracentesis, topical beta-
blockers, aspirin, and intravenous heparin.15 However, the limited efficacy of all these 
therapies made acute CRA occlusion a potential candidate for endovascular management. 
Several studies have documented successful vessel recanalization with visual improvement 
compared to controls. In most studies, IA alteplase is most commonly used within 4-6 hours 
from symptom onset. The agent is infused via supraselective catheterization of the ophthalmic 
artery. Padolecchia and colleagues showed that intervention within 4.5 hours of ischemic onset 
leads to visual improvement in all patients.33 Studies performed by Arnold, Aldrich, Noble 
and their colleagues showed visual improvement in a significant amount of patients treated 
with IA thrombolysis that ranged from 22% to 93% compared to much lower conventionally-
treated controls 34-36. The IA agent was r-tPA or urokinase and the treatment time varied from 
6 to 15 hours from symptom onset. Ischemic and hemorrhagic complications were either not 
present (Arnold, Aldrich) or occurred at significantly low rates (Noble).  
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4.2 Posterior circulation 
Acute basilar artery (BA) occlusion is a life-threatening event that poses a significant 
therapeutic challenge. The natural progression of untreated BA occlusion has mortality rates 
ranging from 86% to 100%.15 The rare incidence of this disease, less than 10% of acute ischemic 
strokes, could account for the lack of significant randomized controlled studies in the topic. 
Several meta-analyses of case reports and case series reflect the severity of the disease. In a 
series of nearly 300 patients, Furlan and Higashida reported an IA recanalization rate of 60%, 
and mortality rates of 31% in at least partially recanalized patients as opposed to 90% in non-
recanalized patients.37 Lindsberg and Mattle compared BA occlusion treatment with IV or IA 
thrombolysis. They found that although recanalization rates were higher with IA treatement 
(65% versus 53%), dependency or death rates were equal between the two groups (76-78%). 
Overall, 22% of treated patients had good outcomes, as opposed to only 2% of untreated 
individuals. Therefore, emergent thrombolysis via either technique is of paramount 
importance to the survival of this patient population. 
The timing of treatment initiation in relation to symptom onset is a controversial topic. 
Theoretically, the same treatment restrictions apply as in the anterior circulation, however, in 
practice, the therapeutic window can be successfully extended beyond 6 hours. In our 
institution, we have achieved favorable clinical outcomes in patients treated up to 12 hours 
from symptom onset. Between 12 and 18 hours, incidence of hemorrhagic conversion is more 
significant, and treatment is rarely extended beyond the 24-hour window. In the Basilar Artery 
International Cooporation Study (BASICS), 624 patients with radiographically confirmed 
occlusion of the BA were enrolled in nearly 50 centers over a 5-year period.38 All patients 
(n=41) treated with IA or IV thrombolytics beyond 9 hours from symptom onset had a poor 
reported outcome.  
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Fig. 2. A-F. Acute right vertebro-basilar occlusion. A-B. Mid-arterial digital subtraction 
angiogram of the right vertebral artery (dominant) showing complete occlusion with no distal 
filling of the basilar artery, frontal and lateral views. C. Frontal view of balloon angioplasty of 
the right vertebro-basilar junction. D. Road map during deployment of Wingspan stent at the 
vertebro-basilar level. E-F. Frontal and lateral views of right vertebral artery mid-arterial 
angiograms depicting vessel recanalization following mechanical thrombolysis. 
Recent advances in mechanical and pharmacological approaches to endovascular therapies 
may increase BA recanalization rates and improve patient outcome (Fig. 2). In a meta-
analysis of 164 patients with BA occlusion over a 10-year period, Levy et al reported several 
predictive factors in treatment consideration.39  Factors with a negative prognostic value 
were coma at initial presentation, failure of vessel recanalization, and proximal vessel 
occlusion. Distal BA occlusions are more commonly embolic in nature and therefore have a 
better response to thrombolytic agents. 
5. Intra-arterial mechanical thrombolysis 
The use of mechanical endovascular devices for thrombolysis is emerging as a powerful 
adjuvant, or even an alternative to chemical thrombolysis. In their multi-center review, 
Gupta and colleagues have demonstrated that multimodality approach with chemical and 
mechanical thrombolysis leads to higher recanalization rates40. The mechanical disruption of 
the arterial clot has several advantages to IA management of acute stroke.16 First, it increases 
the working surface area for thrombolytic agents thereby enhancing their efficacy. Even 
partial removal of clot via retrieval or thromboaspiration techniques lessens the 
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concentration of IA agent required to dissolve the remainder pieces. As a result, the risk of 
ICH is further decreased and the treatment window could be extended beyond the 6-hour 
limit. Mechanical thrombolysis provides patients with contraindications to anticoagulation 
with a reasonable alternative to endovascular therapy.  
The use of mechanical thrombolysis is associated with several associated risks. The 
endovascular trauma to the blood vessel could cause endothelial damage, permanent 
vascular injury, and ultimately vessel rupture, especially in old friable vessels. The technical 
skills needed for the endovascular navigation of such devices, especially through severely 
occluded segments, are substantial, and require rigorous training. Finally, the dislodged clot 
material could become an embolic source, exposing the already compromised distal 
circulation to additional ischemic risks. 
Overall, the multiple advantages of mechanical endovascular devices have revolutionized 
current therapies of acute ischemic stroke, and are safe adjuvant and/or alternatives to 
chemical thrombolysis in experienced hands. The conceptual basis of such devices can be 
broadly categorized into the following categories: thrombectomy, thromboaspiration, 
thrombus disruption, augmented fibrinolysis, and thrombus entrapment.16 
5.1 Endovascular thrombectomy 
Devices under this category apply a constant force to the clot material at its proximal or distal 
end and facilitate clot removal. Proximal end forces are applied through grasp-like 
attachments, whereas distal end forces are applied via basket-like devices. The advantage of 
these devices is their decreased association with embolic material since there is no attempt for 
mechanical clot disruption. Some of the most widely used examples are the Merci retriever 
(Concentric Medical, Mountain View, California), the Neuronet device (Guidant, Santa Clara, 
California), the Phenox clot retriever (Phenox, Bochum, Germany), the Catch thrombectomy 
device (Balt Extrusion, Montmorency, France), and the Alligator retrieval device (Chestnut 
Medical Technologies, Menlo Park, California).16  The Merci device became FDA-approved in 
2004 for the endovascular clot retrieval in acute ischemic stroke.41 It is a flexible nitinol wire 
with coil loops that incorporate into the clot and facilitate retrieval. Recent analysis of the 
Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi Merci trials showed 
that patients with M2 occlusions had higher recanalization rates, decreased procedure 
duration and similar complication rates with M1 occlusion patients42. In a recent study that 
investigated the efficacy of current thrombectomy mechanisms, the Merci, Phenox, and Catch 
devices presented equal results with clot mobilization and retrieval.43 
5.2 Endovascular thromboaspiration 
The functioning mechanism in this category utilizes an aspiration technique, which is suited 
for fresh non-adhesive clots. These devices also have the advantage of fewer embolic 
material and decreased vasospasm. Some examples in this category are the Penumbra 
system (Penumbra, Alameda, California) and the AngioJet system (Possis Medical, 
Minneapolis, Minnesota).16  The Penumbra system includes a reperfusion catheter that 
aspirates the clot and a ring-shaped retriever (Fig. 3). The favorable results of a prospective 
multi-center trial conducted in the United States and Europe led to the approval of the 
device by the FDA for the endovascular treatment of acute ischemic stroke in 2008.44  The 
AngioJet system uses a high-pressure saline jet for clot agitation and an aspiration catheter 
for retrieval. Technical difficulties with endovascular navigation resulting in vessel injury 
led to the premature discontinuation of its trial in acute ischemic stroke patients.45 
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Fig. 3. A-E. Acute right MCA occlusion. The patient presented 4 hours after an acute event 
of MCA occlusion. A-B. Mid-arterial digital subtraction angiogram of right ICA shows 
complete MCA occlusion at the level of the bifurcation, frontal and lateral views.  
C. Mechanical thrombolysis with Penumbra device showing recanalization of the superior 
M2 division in a frontal high magnification view. D-E. Frontal and lateral views of right ICA 
angiograms following MCA mechanical recanalization.  
5.3 Thrombus disruption 
In this category, mechanical disruption of the clot is accomplished via a microguidewire or a 
snare. Some devices utilizing this mechanism are the EPAR (Endovasix, Belmont, California) 
and the LaTIS laser device (LaTIS, Minneapolis, Minnesota).16 The potential endothelial 
damage with resultant vessel injury, and genesis of embolic material make these devices less 
favorable in the setting of acute ischemic stroke. 
Traditional balloon inflation techniques could also cause central intra-arterial clot disruption 
and vessel recanalization (Fig. 4). The balloon is positioned across the vascular filling defect 
and gently inflated. Typically, a Hyperglide balloon (ev3 Neurovascular, Toledo, CA) is 
utilized for this technique. The final revascularization result and residual clot burden 
determine the possibility of additional stenting across the lesion. 
5.4 Augmented fibrinolysis 
These devices, such as the MicroLysUS infusion catheter (EKOS, Bothell, Washington), 
utilize a sonographic micro-tip to facilitate thrombolysis through ultrasonic vibration.16 As a 
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result, clot removal is augmented without any additional fragment embolization to the 
distal circulation. Recent studies show a favorable outcome with the use of such devices for 
the endovascular management of acute ischemic stroke.46, 47 
5.5 Thrombus entrapment 
The underlying mechanism of these devices utilizes a stent to recanalize the occluded vessel 
and therefore trap the clot between the stent and vessel wall. Besides their use at the site of 
occlusion, stents could recanalize proximal vessels (such as the extracranial ICA) to allow 
device navigation to the site of pathology. Stents can be deployed via a balloon mechanism 
or could be self-expandable. The latter are becoming increasingly popular due to their 
flexibility and ease of navigation. They include the Neuroform stent (Boston Scientific, 
Natick, Massachusetts), the Enterprise stent (Cordis, Miami Lakes, Florida), the LEO stent 
(Balt Extrusion, Montmorency, France), the Solitaire/Solo stent (ev3, Irvine, California), and 
the Wingspan stent (Boston Scientific). The first 4 stents are utilized in stent-assisted coiling 
of wide-neck aneuryms, whereas the Wingspan is the only stent approved for intracranial 
treatment of atherosclerotic disease.16Their use in acute ischemic events has been 
investigated in several trials48-50. Kim and colleagues reported recanalization rates as high as 
71.4% in acute ischemic stroke with the use of Neuroform stent in 14 patients48. In two 
studies investigating the Neuroform and Wingspan stents, recanalization rates ranged from 
67% to 89% and early follow-up (mean of 8 months) showed small (5%) or no restenosis 
rates.51, 52 
 
 
4.A.  
www.intechopen.com
 Acute Ischemic Stroke 
 
138 
4.B.  
4.C.  
www.intechopen.com
 Endovascular Management of Acute Ischemic Stroke 
 
139 
4.D.  
4.E.  
www.intechopen.com
 Acute Ischemic Stroke 
 
140 
4.F.  
Fig. 4. A-F. Acute right ICA occlusion. The patient presented 5 hours after an acute event of 
left hemiplegia. A-B. Mid-arterial digital subtraction angiogram of right CCA shows 
complete ICA occlusion at the level of the ophthalmic artery, frontal and lateral views. 
C-D. Balloon angioplasty across the lesion with a Hyperglide 3x15mm balloon, frontal and 
lateral native angiographic views. E-F. Frontal and lateral views of right ICA angiograms 
following ICA mechanical recanalization.  
6. Alternative reperfusion strategies 
Cerebral reperfusion during acute ischemic stroke can be augmented via alternative strategies 
that utilize an anterograde or retrograde route. Anterograde reperfusion can be facilitated 
systemically with vasopressors leading to global reperfusion by increasing the mean arterial 
blood pressure. Retrograde reperfusion can be facilitated with a transarterial or transvenous 
approach. The transarterial approach involves the endovascular deployment of the NeuroFlo 
device (CoAxia, Maple Grove, Minnesota). This dual balloon catheter allows for partial 
occlusion of the aorta above and below the level of the renal arteries, therefore diverting flow 
away from the systemic and toward the cerebral circulation.53 Several clinical trials are 
currently underway investigating the safety and efficacy of NeuroFlo and similar devices. 
Transvenous retrograde reperfusion is an experimental technique with potential benefit in 
acute ischemic stroke. Animal studies suggest that diversion of blood from the femoral 
artery into the transverse venous sinuses via transvenous catheters could lower infarction 
size and improve neurological outcome in the setting of acute cerebrovascular ischemia.54 
Further investigational human trials are required prior to introducing such a novel concept 
to current stroke therapies. 
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7. Future directions 
Advances in knowledge about pharmacology, endovascular biomechanics, and endothelial 
properties are stimulating research on new diagnostic and therapeutic tools in the 
management of acute ischemic stroke. Currently there are several clinical trials targeting 
neuroendovascular therapy.21 The Interventional Management of Stroke Study III (IMS III) 
is a phase III multicenter clinical trial that continues the investigation of combined IA and IV 
therapies in the management of acute stroke. The SYNTHESIS Expansion trial is a phase III 
clinical study that compares the safety and efficacy of IV thrombolysis to IA chemical and 
mechanical thrombolysis. Future studies may include the individual comparison of 
mechanical devices versus intravenous thrombolytics55. 
Multiple studies are investigating the safety and efficacy of new generation endovascular 
devices, such as the Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke 
(SENTIS). The neurological outcomes of optimal medical management versus IA 
thrombolysis are examined in clinical trials such as RETRIEVE (Randomized Trial of 
Endovascular treatment of Acute Ischemic Stroke Versus Medical Management) and PISTE 
(Pragmatic Ischemic Stroke Thrombectomy Evaluation). Extending the timing of 
endovascular intervention is being evaluated in conjunction with new radiographic 
techniques.  Examples include the DWI and CTP Assessment in the Triage of Wake-Up and 
Late Presenting Strokes Undergoing Neurointervention Trial, and the MR Imaging and 
Recanalization of Stroke Clots During Embolectomy Trial.21 
These and several other upcoming trials will hopefully provide sufficient clinical data for 
the FDA approval of IA agents, the introduction of new endovascular devices, and other 
adjunctive therapies for the management of the acute stroke patient. 
8. Conclusion 
Over the past decade, endovascular intervention has become a mainstay treatment in the 
setting of acute ischemic stroke. Innovative techniques in both chemical and mechanical 
intraarterial thrombolysis increase the safety and efficacy of endovascular management and 
expand its indications in acute cerebral infarction. Additional larger clinical trials are 
warranted for the improvement of the endovascular care of stroke patients resulting in 
faster and safer reperfusion mechanisms.  
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